公开(公告)号：KR102048453B1

公开(公告)日：2019-11-25

申请号：KR1020180039579

申请日：2018-04-05

Applicant: 주식회사 비피도 ,  서울대학교산학협력단

Inventor： 박명수 ,  오소영 ,  권빈 ,  지근억

IPC: C07H3/06 ,  A23L33/10

公开(公告)号：KR1020210043796A

公开(公告)日：2021-04-22

申请号：KR1020190126394

申请日：2019-10-11

Applicant: 가톨릭대학교 산학협력단 ,  주식회사 비피도

Inventor： 지근억 ,  박명수 ,  정윤주 ,  박상준 ,  박성환 ,  조미라 ,  주지현 ,  곽승기 ,  이주하 ,  이선영 ,  문정현 ,  전주연 ,  류재윤

IPC: C12N1/20 ,  A23L33/135 ,  A61P19/02 ,  C12R1/01

Abstract: 본발명은비피도박테리움슈도카테눌라툼 (Bifidobacterium pseudocatenulatum) C-RAPO 균주및 이를포함하는류마티스관절염개선용, 치료용또는예방용조성물에관한것으로, 본발명에서새롭게분리한비피도박테리움슈도카테눌라툼 (Bifidobacteriumpseudocatenulatum) C-RAPO는류마티스관절염치료효과가뛰어나므로류마티스관절염치료제또는류마티스관절염개선용프로바이오틱스소재로유용하게이용될수 있다.

公开(公告)号：KR102141828B1

公开(公告)日：2020-08-06

申请号：KR1020200001476

申请日：2020-01-06

Applicant: 주식회사 비피도

Inventor： 박명수 ,  지근억

IPC: A61B10/00 ,  B01L9/00

公开(公告)号：KR102074445B1

公开(公告)日：2020-02-06

申请号：KR1020180160170

申请日：2018-12-12

Applicant: 주식회사 비피도 ,  가톨릭대학교 산학협력단

Inventor： 지근억 ,  정윤주 ,  박상준 ,  양수영 ,  이현하 ,  박성환 ,  조미라 ,  주지현 ,  곽승기 ,  이주하 ,  김지원 ,  이선영 ,  유준걸 ,  전주연 ,  류재윤

IPC: C12N1/20 ,  A23L33/135 ,  A61K35/745 ,  A61P19/02 ,  A61P29/00 ,  C12R1/01

公开(公告)号：KR102029263B1

公开(公告)日：2019-11-08

申请号：KR1020180055875

申请日：2018-05-16

Applicant: 주식회사 비피도

Inventor： 박명수 ,  오소영 ,  권빈 ,  지근억

IPC: A23L33/125

公开(公告)号：KR1020120045171A

公开(公告)日：2012-05-09

申请号：KR1020100106539

申请日：2010-10-29

Applicant: 주식회사 비피도

Inventor： 지근억 ,  박명수 ,  김명동 ,  서동완

IPC: A61K36/8945 ,  A61P17/00 ,  A61P37/00

Abstract: PURPOSE: A composition containing Dioscorea batatas Decaisne or extract thereof is provided to prevent or treat allergic diseases including anaphylaxis. CONSTITUTION: A composition for preventing or treating allergic diseases contains Dioscorea batatas Decaisne or extract thereof as an active ingredient. The extract is extract liquid prepared by adding solvent to Dioscorea batatas Decaisne or concentrated liquid thereof. The solvent is water, polar solvent of ethanol, and non polar solvent of hexane. The composition is manufactured in the form of a tablet, pill, granule, soft/hard capsule, powder, emulsion, syrup, or pellet.

Abstract translation: 目的：提供含有薯containing皂甙或其提取物的组合物以预防或治疗过敏性疾病，包括过敏反应。 构成：用于预防或治疗过敏性疾病的组合物含有薯contains皂甙或其提取物作为活性成分。 提取物是通过向薯to蓉或其浓缩液中加入溶剂而制备的提取液。 溶剂为水，乙醇的极性溶剂和己烷的非极性溶剂。 组合物以片剂，丸剂，颗粒，软/硬胶囊，粉末，乳剂，糖浆或丸剂的形式制备。

公开(公告)号：KR1020090115280A

公开(公告)日：2009-11-05

申请号：KR1020080041037

申请日：2008-05-01

Applicant: 한림대학교 산학협력단 ,  주식회사 비피도

Inventor： 강영희 ,  지근억 ,  신승용 ,  최정숙 ,  김동수

IPC: A61K31/70 ,  A61K31/704

CPC classification number: A61K31/704 ,  A61K36/258 ,  Y10S514/824

Abstract: PURPOSE: A composition for suppressing monocyte adhesion is provided to prevent cell adhesion to vascularendothelial cell and protect arteriosclerosis. CONSTITUTION: A composition for suppressing monocyte adhesion comprises 0.02-90 wieght% ginsenoside Rh1 of the chemical formula I. The composition also comprises a compound K of chemical formula II. A ginseng extract is produced by extracting a ginseng with water or low alcohol such as methanol, ethanol, and propanol.

Abstract translation: 目的：提供用于抑制单核细胞粘附的组合物，以防止细胞粘附到血管细胞上皮细胞并保护动脉硬化。 构成：用于抑制单核细胞粘附的组合物包含化学式I的0.02-90Wieght％人参皂苷Rh1。该组合物还包含化学式II的化合物K. 人参提取物是通过用水或低级醇如甲醇，乙醇和丙醇提取人参来制备的。

公开(公告)号：KR1020050022669A

公开(公告)日：2005-03-08

申请号：KR1020030060288

申请日：2003-08-29

Applicant: 충북대학교 산학협력단 ,  주식회사 비피도

Inventor： 지근억 ,  박명수 ,  한남수 ,  엄현주

IPC: C12N15/70

CPC classification number: C12N15/746 ,  C12N15/70

Abstract: PURPOSE: Shuttle vectors for Leuconostoc sp. and E. coli are provided, thereby easily transferring genes encoding recombinant proteins into Leuconostic sp. and effectively using Leuconostoc sp. having various advantages in production of recombinant proteins. CONSTITUTION: The shuttle vector pLeuCM for Leuconostoc sp. and E. coli comprises a DNA replication origin of Escherichia coli(E. coli); a DNA replication origin of Leuconostic sp.; a selection marker for E. coli selected from ampicillin resistance gene, chloramphenicol resistance gene, tetracycline resistance gene and leucine amino acid synthesis gene; a selection marker for Leuconostoc sp. selected from chloramphenicol resistance gene, erythromycin resistance gene, kanamycin resistance gene and ampicillin resistance gene; and a multiple cloning site with various restriction enzyme recognition sites, wherein the shuttle vector pLeuCM has the nucleotide sequence of SEQ ID NO:1.

Abstract translation: 目的：用于明串珠菌的穿梭载体 并提供大肠杆菌，从而容易地将编码重组蛋白的基因转移到明串珠菌属中。 并有效地使用明串珠菌 在重组蛋白的生产中具有各种优点。 构成：穿梭载体pLeuCM用于明串珠菌（Leuconostoc sp。） 大肠杆菌包含大肠杆菌（E.coli）的DNA复制起点; 线粒体的DNA复制起点。 选自氨苄青霉素抗性基因，氯霉素抗性基因，四环素抗性基因和亮氨酸氨基酸合成基因的大肠杆菌选择标记; 露肠肠杆菌的选择标记 选自氯霉素抗性基因，红霉素抗性基因，卡那霉素抗性基因和氨苄青霉素抗性基因; 和具有各种限制酶识别位点的多克隆位点，其中穿梭载体pLeuCM具有SEQ ID NO：1的核苷酸序列。

公开(公告)号：KR1020050002742A

公开(公告)日：2005-01-10

申请号：KR1020040104754

申请日：2004-12-13

Applicant: 주식회사 한국토종약초연구소 ,  주식회사 비피도

Inventor： 최진규 ,  지근억 ,  박명수

IPC: A23L1/29

CPC classification number: A23L33/00 ,  A23L33/105

Abstract: PURPOSE: A health supplementary food containing an extract or powder of Salicornia herbacea Linne and a food acceptable additive is provided. It exhibits excellent effect on enhancing intestinal regulation such as the growth of bifidus and lactic acid bacteria. CONSTITUTION: The supplementary food contains 20 parts by weight of Salicornia herbacea powder, 5 parts by weight of bifidus powder, 1 part by weight of lactobacillus powder, 30 part by weight of oligosaccharide and 0.5 parts by weight of vitamin. The effective dosage amount of the Salicornia herbacea extract is 100 to 250mg/kg. For intestinal regulation, the extract or powder of Salicornia herbacea Linne is added to food or beverages in an amount of 0.1 to 12% by weight or 1 to 30g, based on the total weight of the food or 100ml beverage.

Abstract translation: 目的：提供含有Salicornia herbacea Linne提取物或粉末的健康补充食品和食品添加剂。 它对增强肠调节（如双歧杆菌和乳酸菌的生长）表现出极好的效果。 构成：补充食品含有20重量份的Salicornia herbacea粉末，5重量份双歧杆菌粉末，1重量份乳酸杆菌粉末，30重量份寡糖和0.5重量份维生素。 Salicornia herbacea提取物的有效剂量为100〜250mg / kg。 对于肠道调节，基于食物或100ml饮料的总重量，将Salicornia herbacea Linne的提取物或粉末以0.1至12重量％或1至30g的量加入食品或饮料中。

公开(公告)号：KR100442205B1

公开(公告)日：2004-07-30

申请号：KR1020020011078

申请日：2002-02-28

Applicant: 주식회사 비피도

Inventor： 지근억 ,  박명수 ,  이선호 ,  최연배 ,  문성원

IPC: C12N1/20

Abstract: PURPOSE: A microorganism Bifidobacterium lactis producing β- glucosidase and a method for converting isoflavone into isoflavone aglucon using the same are provided, thereby effectively producing isoflavone aglucon. CONSTITUTION: A microorganism Bifidobacterium lactis IF65(KCCM-10347) producing β- glucosidase is provided. A method for converting isoflavone into isoflavone aglucon comprises fermenting isoflavone-containing plants using Bifidobacterium lactis IF65(KCCM-10347), wherein isoflavone-containing plant is selected from soybean, arrowroot, clover, alfalfa, black beans, Glycyrrizae Radix, Medicage sativa L. and pomegranate; the isoflavone-containing plants are pretreated using protease; and the protease is selected from promod, alcalase, neutrase and papain.

Abstract translation: 目的：提供一种产生β-葡萄糖苷酶的微生物乳双歧杆菌以及使用该微生物将异黄酮转化成异黄酮糖苷配基的方法，从而有效地生产异黄酮糖苷配基。 构成：提供了产生β-葡糖苷酶的微生物乳双歧杆菌IF65（KCCM-10347）。 一种将异黄酮转化为异黄酮糖苷配基的方法，包括使用乳双歧杆菌IF65（KCCM-10347）发酵含异黄酮的植物，其中含异黄酮的植物选自大豆，葛根，苜蓿，苜蓿，黑豆，甘草，Medicale sativa L. 和石榴; 含异黄酮的植物用蛋白酶预处理; 并且蛋白酶选自promod，碱性蛋白酶，中性蛋白酶和木瓜蛋白酶。